Micromet shares traded some 3.3% higher on Monday after the small-cap biotech announced that its candidate drug blinatumomab led to remission in almost four-fifths of leukemia patients in a Phase II trial. It also said that a Phase I trial showed the drug induced durable remission in patients with non-Hodgkin lymphoma. Continue reading Biz Brief: Micromet Stock Rises on Cancer Drug Trial Results Biz Brief: Micromet Stock Rises on Cancer Drug Trial Results originally appeared on DailyFinance on Mon, 14 Jun 2010 13:43:00. Filed Under: Investing , Health Care , Sanofi Aventis , Astrazeneca , Biz Brief Permalink | Tweet this! | Comments